PURPOSE: To evaluate erectile function (EF) prospectively from 1 to 2 years post-brachytherapy in patients with a baseline IIEF5 score>16.
METHODS: Between 2007 and 2012, 179 patients underwent an exclusive brachytherapy for localised low risk prostate adenocarcinoma. Neo-adjuvant hormotherapy (15.6%) and post-brachytherapy intake phosphodiesterase inhibitors (PDE5i) were not considered as exclusion criteria. EF was evaluated via a scoring questionnaire IIEF5 before the surgical implantation, at month 12 and 24 post-operation. Only patients with an initial IIEF5 score >16 were included.
RESULTS: Of the 179 patients, 102 (57%) had a baseline IIEF5 >16. At 12 months, 51.1% maintained an IIEF5 >16 and 24.5% had a mild to moderate erectile dysfunction (ED), so that a total of 75.6% with IIEF5 ≥12. About 18% of patients had used PDE5i. At 24 months, 53.2% had an IIEF 5>16 and 80.6% had an IIEF5 ≥12. Severe ED was reported in only 14.5% of the patients. The mean IIEF5 was 16.2 with an average decline of 5 points from the initial stage. All patients who were treated with PDE5i (27%) could have sexual intercourse. EF at baseline was reported as the only predictive factor of ED in multivariate analysis, 70% of patient without ED initially, had an IIEF5 >16 at 1 and 2 years.
CONCLUSION: Severe ED was quite rare (14%) during the first 2 years post-brachytherapy and more than half of patients maintained an IIEF5 >16. The main predictive factor was the erectile function at baseline.
Written by:
Delage F, Perrouin-Verbe MA, Le Fur E, Papin G, Thoulouzan M, Malhaire JP, Pradier O, Fournier G, Valéri A. Are you the author?
Institution(s): See publishing journal.
Reference: Prog Urol. 2014 Nov 16. pii: S1166-7087(14)00624-1.
doi: 10.1016/j.purol.2014.11.002
PubMed Abstract
PMID: 25497176
Article in French.